Know Cancer

forgot password

A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma

Phase 3
18 Years
Open (Enrolling)
Esophageal Squamous Carcinoma

Thank you

Trial Information

A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma

Inclusion Criteria:

1. Histologically confirmed squamous cell carcinoma of esophagus or Esophagogastric

2. Age >= 18

3. ECOG PS 0-2

4. Ineligibility for surgery

5. No prior palliative therapy

6. At least one bidimensionally measurable disease as defined by RECIST ver 1.1

7. Adequate organ function for treatment

- Absolute neutrophil count (ANC)>=1000cells/mm3

- Platelets >=100000 cells/mm3

- Estimated creatinine clearance>=50mL/min, or serum creatinine<1.5 x institution
upper limit of normal

- Bilirubin=<1.5 x upper limit of normal(ULN)

- AST(SGOT)=<2.5 x ULN (5.0xULN if hepatic metastases)

- ALT(SGPT)=<2.5 x ULN (5.0xULN if hepatic metastases)

- 12-Lead electrocardiogram(ECG) with normal tracing or non-clinically significant
changes that do not require medical intervention

- QTc interval =<470 msec and without history of Torsades de Points or other
symptomatic QTc abnormality

- LVEF (by MUGA or echocardiogram) of >=50%.

8. The patient has provided signed informed consent and is amenable to compliance with
protocol schedules and testing.

Exclusion Criteria:

1. Previous treatment with small molecule EGFR tyrosine kinase inhibitors

2. Any major operation within 4 weeks of baseline disease assessment

3. Any clinically significant gastrointestinal abnormalities which may impair intake or
absorption of the study drug

4. CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease

5. Patients with known interstitial lung disease

6. Patients with uncontrolled or significant cardiovascular disease (AMI within 12
months,Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure
or left ventricular ejection fraction below local institutional lower limit of normal
or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia,
Any uncontrolled second or third degree heart block, Uncontrolled hypertension)

7. Previous or concurrent malignancy except for basal or squamous cell skin cancer
and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and
without evidence of recurrence for at least 5 years prior to study entry.

8. Pregnant or breast-feeding women

9. Other severe acute or chronic medical condition or laboratory abnormality that may
increase the risk associated with trial participation or investigational product
administration or may interfere with the interpretation of trial results and, in the
judgment of the investigator, would make the patient inappropriate for entry into
this trial.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival

Outcome Time Frame:

2 year

Safety Issue:


Principal Investigator

Xu jianming, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Affiliated Hospital of the Chinese Academy of Military Medical Science


China: Ethics Committee

Study ID:




Start Date:

November 2012

Completion Date:

November 2014

Related Keywords:

  • Esophageal Squamous Carcinoma
  • Esophageal Squamous Carcinoma
  • Erlotinib
  • Chemoradiotherapy
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Esophageal Diseases